Pages that link to "Q48485316"

The following pages link to Efavirenz and chronic neuropsychiatric symptoms: a cross-sectional case control study (Q48485316):

Displaying 45 items.

• Antidepressants for depression in adults with HIV infection (Q24194669) (← links)
• Efavirenz and the CNS: what we already know and questions that need to be answered (Q28085028) (← links)
• Neurological and psychiatric tolerability of rilpivirine (TMC278) vs. efavirenz in treatment-naïve, HIV-1-infected patients at 48 weeks (Q34035045) (← links)
• Long-term impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals (ACTG 5097s) (Q34216364) (← links)
• Potential benefits of cyproheptadine in HIV-positive patients under treatment with antiretroviral drugs including efavirenz (Q34310827) (← links)
• Laser capture microdissection assessment of virus compartmentalization in the central nervous systems of macaques infected with neurovirulent simian immunodeficiency virus (Q34747341) (← links)
• Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study (Q34756398) (← links)
• Long-Term Safety from the Raltegravir Clinical Development Program (Q35701258) (← links)
• Neurobehavioral Manifestations of Human Immunodeficiency Virus/AIDS: Diagnosis and Treatment (Q36330202) (← links)
• Dendritic spine injury induced by the 8-hydroxy metabolite of efavirenz (Q36406259) (← links)
• Neuropsychometric correlates of efavirenz pharmacokinetics and pharmacogenetics following a single oral dose (Q36729929) (← links)
• Psychiatric and substance abuse comorbidity among HIV seropositive and HIV seronegative prisoners in Malaysia (Q36843549) (← links)
• Depression and Oral FTC/TDF Pre-exposure Prophylaxis (PrEP) Among Men and Transgender Women Who Have Sex With Men (MSM/TGW). (Q36994977) (← links)
• Antiretroviral therapy and central nervous system HIV type 1 infection (Q37066982) (← links)
• Evaluating sleep and cognition in HIV (Q37294737) (← links)
• Single tablet regimens are associated with reduced Efavirenz withdrawal in antiretroviral therapy naïve or switching for simplification HIV-infected patients (Q37501229) (← links)
• Implications of efavirenz for neuropsychiatry: a review. (Q37801927) (← links)
• Oral Preexposure Anti-HIV Prophylaxis for High-Risk U.S. Populations: Current Considerations in Light of New Findings (Q37834013) (← links)
• A Systematic Review of the Psychiatric Side-Effects of Efavirenz (Q37864141) (← links)
• Antiretroviral drug toxicity in relation to pharmacokinetics, metabolic profile and pharmacogenetics (Q37866298) (← links)
• HIV-associated neurological disorders: a guide to pharmacotherapy (Q37971469) (← links)
• Discontinuation of efavirenz therapy in HIV patients due to neuropsychiatric adverse effects (Q38083294) (← links)
• A review of trials investigating efavirenz-induced neuropsychiatric side effects and the implications (Q38743628) (← links)
• Cost considerations in the current antiretroviral era. (Q39194185) (← links)
• Effect of Valerian in Preventing Neuropsychiatric Adverse Effects of Efavirenz in HIV-Positive Patients: A Pilot Randomized, Placebo-Controlled Clinical Trial (Q40223622) (← links)
• Depression and anxiety were low amongst virally suppressed, long-term treated HIV-infected individuals enrolled in a public sector antiretroviral program in Thailand (Q40523281) (← links)
• Acute psychosis as a side effect of efavirenz therapy with metabolic anomalies: an important differential diagnosis of HIV-associated psychoses (Q41748068) (← links)
• Molecular mechanisms of serotonergic action of the HIV-1 antiretroviral efavirenz (Q42592784) (← links)
• NeuroAIDS: a watershed for mental health and nervous system disorders (Q43174607) (← links)
• Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial (Q43300648) (← links)
• Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection (Q43651001) (← links)
• Effects of the HIV treatment drugs nevirapine and efavirenz on brain creatine kinase activity. (Q43869691) (← links)
• HIV-1 infection and cognitive impairment in the cART era: a review (Q46860049) (← links)
• Efavirenz is related to neuropsychiatric symptoms among adults, but not among adolescents living with human immunodeficiency virus in Kilimanjaro, Tanzania. (Q47567926) (← links)
• Anti-HIV drugs nevirapine and efavirenz affect anxiety-related behavior and cognitive performance in mice. (Q48240154) (← links)
• Dream changes following initiation of efavirenz treatment (Q48335733) (← links)
• Depression associated with antiretroviral drug therapy in HIV: case report and overview (Q48642405) (← links)
• Emerging reverse transcriptase inhibitors for HIV-1 infection. (Q53686168) (← links)
• Incidence of neuropsychiatric side effects of efavirenz in HIV-positive treatment-naïve patients in public-sector clinics in the Eastern Cape. (Q53759304) (← links)
• HIV and mental illness in Malawi and the neuropsychiatric sequelae of efavirenz. (Q55344050) (← links)
• Environmental fate and ecotoxicological effects of antiretrovirals: A current global status and future perspectives (Q57170516) (← links)
• Non-Nucleoside Reverse Transcriptase Inhibitors Efavirenz and Nevirapine Inhibit Cytochrome C Oxidase in Mouse Brain Regions (Q60492089) (← links)
• Psychiatric outcomes observed in patients living with HIV using six common core antiretrovirals in the Observational Pharmaco-Epidemiology Research and Analysis database (Q64320510) (← links)
• Factors associated with loss-to-follow-up of HIV-positive mothers and their infants enrolled in HIV care clinic: A qualitative study (Q90115157) (← links)
• Improved Central Nervous System Symptoms in People with HIV without Objective Neuropsychiatric Complaints Switching from Efavirenz to Rilpivirine Containing cART (Q92570343) (← links)